Compare MDV & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | ALXO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.5M | 205.9M |
| IPO Year | N/A | 2020 |
| Metric | MDV | ALXO |
|---|---|---|
| Price | $17.24 | $1.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $18.00 | $3.50 |
| AVG Volume (30 Days) | 51.5K | ★ 818.2K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.80 | $0.51 |
| 52 Week High | $18.96 | $2.66 |
| Indicator | MDV | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 46.61 |
| Support Level | $13.95 | $1.56 |
| Resistance Level | $18.82 | $2.27 |
| Average True Range (ATR) | 0.44 | 0.13 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 9.80 | 22.58 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in, and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from the company's consolidated real estate properties.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.